Commonly Used Drug Can Make Men Stop Enjoying Sex—Irreversibly
No one should have to choose between their hairline and their health. But increasingly, men who use finasteride, commonly known as Propecia, to treat their male pattern baldness are making that choice, often unwittingly. In the 17 years since Propecia was approved to treat hair loss from male pattern baldness, many disturbing side effects have emerged, the term post-finasteride syndrome (PFS) has been coined and hundreds of lawsuits have been brought.
Finasteride inhibits a steroid responsible for converting testosterone into 5α-dihydrotestosterone (DHT) the hormone that tells hair follicles on the scalp to stop producing hair. Years before Propecia was approved to grow hair, finasteride was being used in drugs like Proscar, Avodart and Jalyn to treat an enlarged prostate gland (benign prostatic hyperplasia). Like Viagra, which began as a blood pressure med, or the eyelash-growing drug Latisse, which began as a glaucoma drug, finasteride's hair restoration abilities were a fortuitous side effect.
Since Propecia was approved for sale in 1997, its label has warned about sexual side effects. "A small number of men experienced certain sexual side effects, such as less desire for sex, difficulty in achieving an erection, or a decrease in the amount of semen," it read. "Each of these side effects occurred in less than 2% of men and went away in men who stopped taking Propecia because of them." (The label also warned about gynecomastia, the enlargement of male breast tissue.)
But increasingly, users and some doctors are saying the symptoms sometimes do not go away when men stop taking Propecia and that their lives can be changed permanently. They report impotence, lack of sexual desire, depression and suicidal thoughts and even a reduction in thesize of penises ortesticles after using the drug, which does not go away after discontinuation.
According to surgeon Andrew Rynne, former head of the Irish Family Planning Association, Merck, which makes Propecia and Proscar, knows that the disturbing symptoms do not always vanish. "They know it is not true because I and hundreds of other doctors and thousands of patients have told them that these side effects do not always go away when you stop taking Propecia. We continue to be ignored, of course."
In some cases, says Rynne, men who have used finasteride for even a few months "have unwittingly condemned themselves to a lifetime of sexual anhedonia" [condition in which an individual feels no sexual pleasure], the most horrible and cruel of all sexual dysfunctions."
"I have spoken to several young men in my clinic in Kildare who continue to suffer from sexual anaesthesia and for whom all sexual pleasure and feelings have been obliterated for all time. I have felt their suffering and shared their devastation," he wrote on a Propecia help site.
Sarah Temori, who launched a petition to have finasteride taken off the market on Change.org, agrees. "Many who have taken Propecia have lost their marriages, jobs and some have committed suicide due to the damage this drug has done to their bodies," she writes. "One of my loved ones is a victim of this drug. It's painful to see how much he has to struggle just to make it through each day and do all the daily things that we take for granted. No doctors have been able to help him and he is struggling to pay for medical bills. He is only 23."
Stories about Propecia's disturbing and underreported side effects have run onCNN, ABC, CBS, NBC, Fox and on Italian and English TV news.
The medical literature has also investigated finasteride effects. A study last year in Journal of Sexual Medicine noted "changes related to the urogenital system in terms of semen quality and decreased ejaculate volume, reduction in penis size, penile curvature or reduced sensation, fewer spontaneous erections, decreased testicular size, testicular pain, and prostatitis." Many subjects also noted a "disconnection between the mental and physical aspects of sexual function," and changes in mental abilities, sleeping patterns, and/or depressive symptoms.
A study this year in the Journal of Steroid Biochemistry and Molecular Biology finds that "altered levels of neuroactive steroids, associated with depression symptoms, are present in androgenic alopecia patients even after discontinuation of the finasteride treatment."
Approved in Haste, Regretted in Leisure
The rise and fall of Propecia parallels other drugs like Vioxx or hormone replacement therapy that were marketed to wide demographics even as safety questions nipped at their heels. Two-thirds of American men have some hair loss by age 35, and 85 percent of men have some hair loss by age 50, so Propecia had the promise of a blockbuster like Lipitor or Viagra.
Early ads likened men's thinning scalps to crop circles. Later, ads likened saving scalp hair to saving the whalesand won awards. Many Propecia ads tried to take away the stigma of hair loss and its treatment. "You'd be surprised who's treated their hair loss," said one print ad depicting athletic, 20-something men. In 1999 alone, Merck spent $100 million marketing Propecia directly to consumers, when direct-to-consumer advertising was just beginning on TV.
Nor was Propecia sold only in the U.S. Overseas ads compared twins who did and did not use the product. In the U.K., the drugstore chain Boots aggressively marketed Propecia at its 300 stores and still does. One estimates says Propecia was marketed in 120 countries.
Many have heard of "indication creep," when a drug, after its original FDA approval, goes on to be approved for myriad other uses. Seroquel, originally approved for schizophrenia, is now approved as an add-on drug for depression and even for use in children. Cymbalta, originally approval as an antidepressant, went on to be approved for chronic musculoskeletal pain.
Less publicized is "warning creep," when a drug that seemed safe enough for the FDA to approve, collects warning after warning once the public is using it. The poster child for warning creep is the bone drug Fosamax. After it was approved and in wide use, warnings began to surface about heart problems, intractable pain, jawbone death, esophageal cancer and even the bone fractures it was supposed to prevent. Oops.
But finasteride may do Fosamax proud. In 2003, it gained a warning for patients to promptly report any "changes in their breasts, such as lumps, pain or nipple discharge, to their physician." Soon, "male breast cancer" was added under "postmarketing experience." In 2010 depression was added as a side effect and patients were warned that finasteride could have an effect on prostate-specific antigen (PSA) tests. In 2011, the label conceded that sexual dysfunction could continue "after stopping the medication" and that finasteride could pose a "risk of high-grade prostate cancer." In 2012, a warning was added that "other urological conditions" should be considered before taking finasteride. In 2013, the side effect of angioedema was added.
A quick look at Propecia approval documents does not inspire confidence. Finasteride induces such harm in the fetuses of lab animals, it is contraindicated in women when they are or may potentially be pregnant and women should not even "handle crushed or broken Propecia tablets when they are pregnant."
Clinical trials were of short duration and some only had 15 participants. While subjects were asked aesthetic questions about their hairline during and after clinical trials, conspicuously absent on the data set were questions about depression, mental health and shrinking sexual organs.
In one report an FDA reviewer notes that Merck did not name or include other drugs used by subjects during trials, such as antidepressants or GERD meds, suggesting that depression could have been a known side effect of Propecia. Elsewhere an FDA reviewer cautions that "low figures" in the safety update are not necessarily reliable because the time period was "relatively short" and subjects with sexual adverse events may have already "exited from the study." An FDA reviewer also wrote that "long-term cancer effects are unknown." Breast cancer was noted as an adverse event seen in the trials.
Propecia Users Speak Out
There are many Propecia horror stories on sites founded to help people with side effects and those involved in litigation. In 2011, a mother told CBS news she blamed her 22-year-old son's suicide on Propecia and Men's Journal ran a report called "The (Not So Hard) Truth About Hair Loss Drugs."
In a database of more than 13,000 finasteride adverse effects reported to the FDA, there were 619 reports of depression and 580 reports of anxiety. Sixty-eight users of finasteride reported a "penis disorder" and small numbers reported "penis deviation," "penis fracture" and "micropenis."
On the patient drug review site Askapatient.com, the 435 reviews of Propecia cite many examples of depression, sexual dysfunction and shrunken penises.
One of the most visible faces for post-finasteride syndrome is 36-year-old UK resident Paul Innes. Previously healthy and a soccer player, Innes was so debilitated by his use of Propecia, prescribed by his doctor, he founded a web siteand has gone public. Appearing on This Morning last month, Innes describes how using Propecia for only three months on one occasion and three weeks on another produced a suicidal depression requiring hospitalization, sexual dysfunction and a reduction of the size of his reproductive anatomy, none of which went away when he ceased the drug. He and his former girlfriend, Hayley Waudby, described how the physical and emotional changes cost them their relationship, even though she was pregnant with his child.
In an email I asked Paul Innes if his health had improved after the ordeal. He wrote back, "My health is just the same if not worse since 2013. I am still impotent with a shrunken penis and still have very dark thoughts and currently having to take antidepressants just to get through every day. Prior to Propecia I was a very healthy guy but now I'm a shadow of my former self. I have only just managed to return to work in my role as a police officer since taking Propecia in March 2013."